What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Virus
Peter Aaby focuses on Pediatrics, Immunology, Vaccination, Measles and Measles vaccine.
His Pediatrics research includes elements of Epidemiology, Mortality rate, Randomized controlled trial, Child mortality and Infant mortality.
His research integrates issues of Internal medicine, Incidence, Cohort study and Tuberculosis in his study of Immunology.
Peter Aaby has researched Vaccination in several fields, including Tuberculosis vaccines, Heterologous and Immunization.
His Measles research includes elements of Viral disease, Case fatality rate, Vaccine efficacy and Serology.
Peter Aaby usually deals with Measles vaccine and limits it to topics linked to Standardized mortality ratio and Cause of death.
His most cited work include:
- The Danish National Birth Cohort - its background, structure and aim: (812 citations)
- Measles and atopy in Guinea-Bissau (529 citations)
- A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. (397 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Pediatrics, Vaccination, Immunology, Measles and Measles vaccine.
The various areas that Peter Aaby examines in his Pediatrics study include Epidemiology, Mortality rate, Randomized controlled trial, Child mortality and Infant mortality.
His work in the fields of BCG vaccine, Tetanus and Diphtheria overlaps with other areas such as Guinea bissau.
His Immunology research is multidisciplinary, incorporating perspectives in Internal medicine, Incidence, Cohort study and Tuberculosis.
His study in Measles is interdisciplinary in nature, drawing from both Viral disease, Case fatality rate and Vaccine efficacy.
His Measles vaccine research is multidisciplinary, relying on both Poliomyelitis, Standardized mortality ratio and Hazard ratio.
He most often published in these fields:
- Pediatrics (62.68%)
- Vaccination (56.11%)
- Immunology (36.79%)
What were the highlights of his more recent work (between 2018-2021)?
- Vaccination (56.11%)
- Pediatrics (62.68%)
- Measles vaccine (34.43%)
In recent papers he was focusing on the following fields of study:
Peter Aaby mostly deals with Vaccination, Pediatrics, Measles vaccine, Measles and Mortality rate.
His Vaccination study incorporates themes from Internal medicine, Randomized controlled trial, Proportional hazards model and Tuberculosis.
His Pediatrics study combines topics in areas such as Lower mortality, Diphtheria, Tetanus, Public health and Prospective cohort study.
His Measles vaccine research integrates issues from Diphtheria tetanus pertussis, Poliomyelitis and Child mortality.
His work deals with themes such as Psychological intervention, Attenuated vaccine and Clinical trial, which intersect with Measles.
His BCG vaccine research is classified as research in Immunology.
Between 2018 and 2021, his most popular works were:
- Outcomes of controlled human malaria infection after BCG vaccination. (57 citations)
- The COVID-19 pandemic: diverse contexts; different epidemics-how and why? (39 citations)
- Can existing live vaccines prevent COVID-19? (39 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Virus
Peter Aaby focuses on Vaccination, Randomized controlled trial, Measles, Tuberculosis and Pediatrics.
His Vaccination research is under the purview of Immunology.
His Randomized controlled trial research is multidisciplinary, incorporating elements of Odds ratio and Confidence interval.
His study in Measles focuses on Measles vaccine in particular.
As a member of one scientific family, he mostly works in the field of Tuberculosis, focusing on Observational study and, on occasion, Rabies, Intensive care medicine and Clinical trial.
His research ties Public health and Pediatrics together.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
